Evidence demonstrated that following intravenous administration of gedatolisib, it inhibits both mTOR and PI3K kinases, inducing apoptosis and suppressing the growth of tumor cells overexpressing PI3K/mTOR. This evidence concerns the gene PIK3CA and neoplasm.